MGMT and central nervous system cancer: B1-907828, another potent mdm2 inhibitor, suppressed cell viability (IC50 of 21.1–424.9 pM) on wt-p53 human glioma tumor stem cells (GTSC) with several Mdm2 amplification levels and different MGMT promoter methylation statuses.